Monday, 20 Nov 2017

You are here

Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?

There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis (RA).

Trials like TEAR, RACAT and SWEFOT have show similar and disparate results.

Researchers preformed a systematic review and network meta-analysis (NMA) of randomised controlled trials comparing TNFi-methotrexate or triple therapy. Interestingly, the primary endpoint of this analysis was an ACR 70% response (ACR70) at 6 months. 

Researchers analyzed 33 studies in patients with inadequate response to methotrexate (established RA) and 19 in patients naive to methotrexate (early RA).

Established RA - Inadequate response to MTX

Figure 2

In inadequate responders, triple therapy was associated with lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate (OR 0.35, 95% credible interval (CrI) 0.19 to 0.64). Although several secondary endpoints trended towards favoring the TNFi-methotrexate arm, there was no significant advantage for either therapy.

For those who were MTX naive, there was no advantage of either therapy with regard to the primary endpoint. Although those treated with TNFi–methotrexate were more likely to achieve ACR70 and have less X-ray progression at 2 years, this was only seen in the fixed-effects analyses and not the random-effects models. The magnitude of this effect was not felt to not be clinically relevant. 

With regard to safety, infections were lower with triple therapy than with TNFi-methotrexate (OR 0.08, 95% CrI 0.00 to 0.57). There were no differences observed between the two regimens in patients naive to methotrexate.

For those with an inadequate response to methotrexate, triple therapy was associated with 65% lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate in patients.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.